FDA approves new injectable drug to treat schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

Source: Food and Drug Administration - October 6, 2015 Category: American Health Source Type: news